@article{1ea62780713e46dc97f62ccf23aa42ef,
title = "Forecasting cancer: from precision to predictive medicine",
abstract = "Tumor evolution drives tumor progression, therapeutic resistance, and metastasis. Therefore, new predictive medicine strategies that adapt with a tumor are needed to improve patient outcomes. The techniques used in weather prediction are mathematically proven to enable prediction of evolving systems, and thus provide a framework for a new predictive medicine paradigm for cancer.",
author = "Fertig, {Elana J.} and Jaffee, {Elizabeth M.} and Paul Macklin and Vered Stearns and Chenguang Wang",
note = "Funding Information: E.J.F. is on the Scientific Advisory Board of Viosera Therapeutics/Resistance Bio. E.M.J. is a paid consultant for Adaptive Biotech, CSTONE, Achilles, DragonFly, and Genocea; receives funding from the Lustgarten Foundation and Bristol Meyer Squibb; and is the chief medical advisor for Lustgarten and an SAB advisor to the Parker Institute for Cancer Immunotherapy (PICI) and for the C3 Cancer Institute. V.S. received research grants to the institution from Abbvie, Biocept, Pfizer, Novartis, and Puma Biotechnology and is a Member, Data Safety Monitoring Board, Immunomedics, Inc. C.W. has a professional affiliation with Regeneron Pharmaceuticals. Funding Information: Funding for the authors provided by Lustgarten Foundation (E.J.F. and E.M.J.), the Emerson Collective (E.J.F. and E.M.J.), the Johns Hopkins University Discovery Award (E.J.F.), Jayne Koskinas Ted Giovanis Foundation for Health and Policy (P.M.), Cancer MoonshotSM funds from the National Cancer Institute (P.M.), Leidos Biomedical Research Subcontract 21X126F (P.M.), and the NIH/NCI (U01CA232137 to P.M., U01CA212007 to E.J.F., U01CA253403 to E.J.F., and P01CA247886 to E.J.F. and E.M.J.). Funding Information: Funding for the authors provided by Lustgarten Foundation (E.J.F. and E.M.J.), the Emerson Collective (E.J.F. and E.M.J.), the Johns Hopkins University Discovery Award (E.J.F.), Jayne Koskinas Ted Giovanis Foundation for Health and Policy (P.M.), Cancer MoonshotSM funds from the National Cancer Institute (P.M.), Leidos Biomedical Research Subcontract 21X126F (P.M.), and the NIH/NCI (U01CA232137 to P.M. U01CA212007 to E.J.F. U01CA253403 to E.J.F. and P01CA247886 to E.J.F. and E.M.J.). E.J.F. is on the Scientific Advisory Board of Viosera Therapeutics/Resistance Bio. E.M.J. is a paid consultant for Adaptive Biotech, CSTONE, Achilles, DragonFly, and Genocea; receives funding from the Lustgarten Foundation and Bristol Meyer Squibb; and is the chief medical advisor for Lustgarten and an SAB advisor to the Parker Institute for Cancer Immunotherapy (PICI) and for the C3 Cancer Institute. V.S. received research grants to the institution from Abbvie, Biocept, Pfizer, Novartis, and Puma Biotechnology and is a Member, Data Safety Monitoring Board, Immunomedics, Inc. C.W. has a professional affiliation with Regeneron Pharmaceuticals. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = sep,
day = "10",
doi = "10.1016/j.medj.2021.08.007",
language = "English (US)",
volume = "2",
pages = "1004--1010",
journal = "Med",
issn = "2666-6359",
publisher = "Cell Press",
number = "9",
}